screeningBehavior
paper
immunohistochemistry
theirPyrrolizin-5-oneAnalogs
filipinoWomen
novelTargetedTherapeuticOptions
nuclearFactors
maintainedBreastCancerDatabase
theirApplication
reality
Areas
edition
yearRfsrate
Isolation
sonography
breastExamination
promisingSupplements
pneumopathy
recurrence
specimen
Aims
deregulatedMirnas
twenty-twoPatients
usedDrugs
frequentCancer
compounds
histology
l-3Knockdown
unenhancedMriTechniques
sites
dysregulation
methylation
feasibilityStudies
neutrophil-to-lymphocyteRatio
handicap
assessment
BRCA1/2
lungCellCarcinomas
genitalTract
resultsExpression
subgroupVariables
symptoms
tumorCells
Analysis
female
SNPs
vulnerability
theirAbility
CESM
betterUnderstanding
strongLinkage
complexTreatmentAlgorithms
sampleSizes
differentialDiagnosis
omega3FattyAcids
appearance
continuousRisk
found
eConcentration
transitionProbabilities
age-matchedSystematicRandom-samplingMethod
theory-basedIntervention
positiveFeedbackLoop
TP53
importantCornerstone
expectedInverseCorrelation
Referrals
mitochondrialTransmembranePotential
summaryHazardRatios
NSAIDs
DAU
severalPatients
MicroRNAs
primaryBreastCarcinoma
interleukin6
antigenIdentification
sialicAcidExpression
therapeuticSequencing
tumorNippleDistance
methods
medianFollow-upPeriod
sexes
characteristics
treatment
stressProbe
estrogenicExposure
conventionalChemotherapyDrugs
post-radiationVascularLesions
RT
dataAnalytics
usExaminations
oneCase
need
Hypoxia
breastCancers
interplay
novelPowerfulTechnique
collectedSignatures
know-howWe
cornerstone
palliativeChemotherapy
breastCancerCare
participants
hypoxia
colorectalCancer
cancerCareCenter
hypomethylation
chinesePublic
functionalAssessments
mainTwoEntities
foodRecommendations
SUMMARY
limited-angleFourier-domainSosReconstruction
blood
caseReport
RANKL
ddtSprays
primaryCareProvider
psychologicalAspects
youngMen
results
fine-needleAspirationCytology
polymorphisms
biologicalSubtypes
resultsDiagnosed
group1
otherFactors
brainMetastases
DDT
invasiveLobularHistology
differentProtocols
agreement
METHODS
exercise
metastaticBreastCancer
leaves
long-termUse
77Patients
antibodyPanel
simulationStudies
sequencing
correlation
performance
ai-associatedTendinopathy
conventionalMagneticResonanceImaging
osteopontin-750Accumulation
bioimpedanceAnalysis
abbreviatedMriProtocols
hereditaryBreast
mutationCarriers
betterUnderstanding
relationship
homologousRecombinationPathway
hormone-dependentPositiveBreastCancer
pax6Inhibition
noninvasiveImaging
oncogenicFunctionality
doses
outcome
forwardProblem
antibody-anchoredMagneticBeads
subtype
responsibleMechanisms
Resurgery
circulatingExosomes
Kazakhstan
methodsDesign
focus
PCDH10
Information
Access
improvedCancerTreatment
furtherImaging
careProvider
heterogeneity
ck5/6
postAssessment
netvizzApplication
tanUsage
tnmStaging
calvarialLesions
binaryLogisticRegressionModels
uptake
resonanceImaging
coding
metastasis
followingStudy
equivalentPerformance
solubleMediators
severalIndividuals
highIndex
expressedCircularRnas
systematicSearch
itsImportantRole
535941Survivors
dysplasia
Report
GTPase
transcriptionFactorForkheadBoxC1
brd4Regulation
postmenopausalPatient
Protocadherin-10
biomarker
breastCancerCases
multiresolutionResult
specificityImprovement
membraneTypeMr
methylationStatus
contribution
contraceptionUse
Radiotherapy
sexualityMoreEvidence
vap-1StainingResults
similarPfs
healthCenters
betterOs
multigenePanels-with
Surgeons
innateImmuneSystems
Using
summary
classifiers
membraneTypeMannoseReceptor
NCCN
identification
cancerControlPlanning
chineseExpertGroup
note
neuropathicPain
effectiveness

objectiveResponseRate
precision
estrogens
tomography
currentFollow-up
mutations
12331Users
otherData
Patients
femalePatients
contrastEnhancement
dictionaryLearning
cross-validation
mainChallenge
miRNAs
included
variants
differentLong-termSurvival
decreasedExpression
survivalDifferences
mostStudies
extensiveExploration
excision
majorObstacle
its
interpretation
neoadjuvantChemotherapy
fisherDiscriminantAnalysis
scarceReports
late-phaseClinicalTrials
genes
LMICs
femaleNudeMice
longScanTime
Overexpression
genitalTract'sMetastases
Investigation
tertiarySexualHealthCenters
components
mastectomies
we
leafExtracts
testing
activation
xenograftMice
screening
late-stageCancerDiagnosis
risks
surgicalOutcome
personalDecision-making
propensityScoreMatchingAnalysis
nondestructiveTests
highVariability
Data
pharmacokineticParameters
menopausalHormoneTherapy
mitochondrialResponse
little
suggesting
Individuals
improvedUnderstanding
ovarianMetastases
subsequentAxillaryLymphNodeDissection
alveolar-interstitialLesions
healthcarePolicyMakers
Angiogenesis
22Patients
Factors
PF
findings
secondLargestHmo
carbonDioxideLaserTechnology
epidemiologicalFeatures
ourResults
coxProportionalHazardRegressionModels
0-5Years
MultipleMyeloma
inclusion
sectionLeads
survivalRate
humanEpidermalGrowthFactorReceptor2ReceptorStatus
hypomethylationSites
cylindricalGeometries
18-fdgFlux
knockdown
suutaneousBreastTumor
molecularTesting
cutoffValue
lungCancer
materialDetection
Images
archivedFormalin-fixedParaffin-embeddedTissue
Findings
deep-CNN
radicalSurgicalApproaches
oestrogenReceptorAlpha
uterineTumors
surfaceArea
mriImaging
mitochondrialFission
clinicalOutcomesDiffer
program
elevatedMitochondrialFission
imagingTechnique
proposedTechniqueResults
allBreastCancerPatients
level
existence
incidence
breastConservation
obstetricians
magneticResonanceImaging
chorea
opticalAbsorptions
symptomaticWomen
brcc3ExpressionLevels
they
propagation-basedPhase-contrast
fastingBlood
tumour
107ObservationalStudies
polymorphismsImportant
sparseCoding
mechanisms
histopathologicalAnalysis
centralImplantedVenousAccessDevices
discovery
parallelDetection
Mammography
world
label-freeDetection
recentStudies
Disease
acromegaly
effects
back-splicingMechanism
commonAdultCancers
DOACS
SPC24
trends
contraceptiveUse
adverseEffects
detailedAnalysis
parameters
insight
40
concurrentNeuroprotectiveDrugTherapy
intrinsicDisruption
excellentPerformance
tenfoldCross-validationMatthew
patient'sMedicalHistory
MRI
technique
differentStudies
prevention
mortalityRates
Aspirin
nationwideSurvey
Prolactinomas
Myeloma
protocol
She
Screening
femalePatients
emergingTechnology
preoperativeUnderstanding
anthracyclineChemotherapyAgents
theirEmergingRole
19
P
adjustedProportion
threeDifferentClusters
guidePatients
20-year-oldWoman
CNVs
mainObjective
RNAs
cohortStudy
easternAsianMusculoskeletalOncologyGroup
recommendations
breastCancerRisk
numericalFull-waveSimulation
considerableNumber
h&eStaining
imbalance
systematicReview
stromalExpression
RDD
bilateralMastectomies
largeBreastCancerTissueMicroarray
node
Identification
signature
lymphedemaseventyPatients
highCorrelation
regulationMechanisms
search
roboticSurgicalSystems
none
conclusionsWomen
SVM-BRC
HADS
survivalData
countries
t2bSutegory
exosomesDerivedCk19
10Mg/kg
score
review
clinico-pathologicalRiskFactors
experience
GDM
intelligentTechniques
decision
five-yearLocalRecurrenceRates
brain
kaplan-meierCurves
mammography
increasingNumber
traditionalPredictors
data
importance
surgicalExcision
84Patients
she
longerPfs
trastuzumab
immunohistochemicalAnalysis
inhibited
increase
pseudotumoralAspect
osRate
double-maintenanceTherapy
understanding
commonCause
picture
mastitis
change
stage
role
boneDensity
aromataseInhibitors
immediateUnmetNeed
hypothesis
suchStandardization
realDataAnalysis
pattern
performed
nsaidExposure
pi3k/aktSignaling
Rainbow
physician
observationalStudies
itsExpression
supplementalScreening
alternativeOption
imageQuality
tumorMarkers
cellDeath
smallPopulation
distinction
maleBreastCancer
54BreastCancerPatients
ourTheoreticalAnalysis
fiveYearRfsrate
lobularCarcinoma
medianOs
clinicalFeatures
differentTreatmentModalities
digitalBreastTomosynthesis
Resection
tediousCountingCell
st-2Level
rnaSequenceAnalysis
restoration
distinctiveGeneticModifications
complexConsulting
thepresence
pain
histologicExamination
controlGroup
density
physicalActivity
theirSurvival
itsWater-bathSetup
supplements
breastConservation
third-degree
theResulting
transmembraneCellDeaths
26894People
phosphotyrosineRegulatedProteinComplexes
greaterthanorequalto10PercecntDecline
95PercecntConfidenceIntervals
textureFeatures
lungCancer
application
tripentoneDerivatives
microRNAs
challenges
aberrantDnaMethylation
mmp2Genes
localControl
sox9NucleusEntry
ctnLevels
Treatment
Demographics
aspirationCytology
featureSubset
selectedOptimalFeatureSubsets
severePneumopathy
unusualImmuneProfiles
essentialsBleedingRisk
severalIntelligentTechniques
essentialRole
cavernousMalformationInduction
knowledgeSummaries
advancedAnalysis
consolidativeRadiotherapy
ourFindings
subacuteEffects
status
scope
multivariableLogisticRegressionAnalysis
flowRate
interventionalProcedures
comparisonCohort
percecntConfidenceIntervals
Depletion
caseRecords
sensor
dynamicSh2Domain-scaffoldingProteinComplexes
subsequentRadiomics
Survival
Trends
evaluation
Japan
capacitance
itsExpressionLevel
comprehensiveSearch
miceConditions
proteins
syndromes
five-yearOsRate
promoterMethylationStatus
itsRelevantLimitations
total
CK19
tumors
breastCancerStudies
ultrasound-guidedDiffuseOpticalTomography
We
profiles
age-basedScreeningPrograms
prophylacticCranialIrradiation
enforcedExpression
mostStigmatization
percecnt
oneSpecificSubtype
dcisDiagnosis
luminalB-likePatients
capabilities
mutationEvents
Symptoms
circulatingBiomarkers
inGrowth
death
mothers
15Percecnt
metastasize
ernGenturis
medianFollow-upPeriod
accuracyScores
sentinelNodeBiopsy
micrometastasis
186Pathology-provenS
rateIncrease
ruralCancerHospital
significantDifference
FXYD3
yoga
elevatedLesion
greatProgress
ongoingTrials
associations
largerStudies
knowledge
function
ourResults
controls
nudeMice
lesion
Metastases
Granuloma
proteinKinaseCInhibitors
Review
importantPotential
positiveChanges
youngPatients
coreNeedleBiopsy
Mfn1
cell
claimsDatabase
complication
rate
morphology
ruralSetting
patients
beta-Sitosterol-d-glucoside
familyHistory
fiveMutationCarriers
survey
recurrentHyperprolactinemia
first
dualRole
clinicalApplicability
miR-511
surgicalImplantationReconstruction
specificEralpha-targetedProbe
commonFinding
rnaOligonucleotides
activeDerivatives
analysis
multidrugResistance
mastectomy
cancer
osteopontin-basedProbe
independentReviewers
manyBreastCancerPatients
sister
20
tract'sMetastases
0.84
adult1-yearCancerSurvivors
Patients
antibodyHerceptin
potential
lipidProfiles
aberrations
466Percecnt
11HereditaryBreastCancerGenes
antibodies
probe
cross-sectionalStudy
infiltrationSimilar
overexpression
ELISA
2060Women
S7
stereotacticWire-guidedBiopsy
andfemales
paraneoplasticAntibodyPanel
bestAvailableEvidence
murineMonoclonalAntibodies
manyFeatures
They
action
ca125-richExosomes
Change
commonComplaint
ctcCounts
olderWomen
t2Category
women
poly
localTherapy
specificFoodRecommendations
feasibleCtcIsolationTechniques
nsclcSamples
disease
2-groupRandomizedControlTrial
heartFailure
locoregionalRadiotherapy
targetedTumorAccumulation
CK
education
averageRisk
neoadjuvantChemotherapyGroups
crcPatients
interactionEffects
APBI
hyperthermia
molecularAnalyses
information
oneCancer
description
furtherUnderstanding
typicalWoman
subset
408
goodTolerabilitytheApatinib
advance
Mutations
epigeneticChanges
troponins
researchDevelopment
HR
oncologicRisk
CLB-Pt-CLB
prognosis
strongAssociation
case
finalMultipleRegressionModel
short-termStrategy
metastases
costs
hereditaryDiffuseGastricCancer
cpgIslands
cm
concentrations
breastCancerControl
malformationInduction
carbohydrateRestriction
improvement
606Percecnt
Downregulation
sentinelLymphNodeBiopsy
pharmacokineticParameters
mammographicBreastCancerScreening
anti-ronMonoclonalAntibodyZt/g4-drugMonomethylAuristatinEConjugate
EosinophilicGranuloma
massMedia
This
particleSwarmOptimizationAlgorithm
smallMoleculeInhibitors
leucocytes
epigeneticMarkers
guidedImagery
occurring
simulatedInnerBreastTissue
procedures
fxyd3Amplification
synthesisMethods
resistantCells
krukenbergTumors
Anthracyclines
HT
primaryBreastDiffuseLargeB-cellLymphoma
years
tissues
cent
proteinKinaseCInhibition
treatmentCompletion
ourData
uterineMass
probeNir-sn-ggt
p
diagnosisSystem
article
Irradiation
cytogeneticAnalysis
initialResults
dose-dependentReduction
history
cancerRiskPerception
itsRelativeClinicalSignificance
risk-stratifiedScreeningStrategy
MetastaticLesions
rural-basedTertiaryCancerCareCenter
purpose
survival
9h-pyridoPyrrolizin-9-one
apoptosis
breastCancerDiagnosis
brainMetastases
shapes
cytology
random-samplingMethod
greatPromise
mildHyperthermia
breastCarcinoma
imaging
meanTime
issues
obstruction
recentDanishCohortStudy
mutationRatio
receiving
highHeterogeneity
80
prophylacticBilateralSalpingo-oophorectomy
sensitiveNano-genosensor
impact
pathogenicVariants
newSignalPattern
aspect
2Patients
similarTowaveletFilter
individuals
gonadotropin
zero-inflatedPoissonRegression
previousTherapy
causes
shift
catheter-relatedObstruction
secondaryLymphedema
cell-killingEffect
77
volume
Cell
mir-511Overexpression
endocrineResistance
plasticity
solubleSt-2Level
factor-1Scores
learning
advancedStage
diagnosticPfBiomarkers
bLymphocyteChemoattractant
anticipatedOutcome
risk-reducingStrategies
migration
pfh-ptx@plgaSpio-her
symptomaticHeartFailure
actualIncidence
panel
otherSignificantConcerns
conditions
l-3
medianDiagnosisAge
conjugatedEquineEstrogen
biopsy
diagnosed
ductalCarcinoma
Cancer
44Percecnt
medianProgression-freeSurvival
five
forty-twoHigh-gradeSarcomas
itsRole
mass
hugeVolumes
otherDietaryRecommendations
Metastasis
potentNon-secosteroidalVdrModulator
sutegories
studyObjective
trastuzumab/pertuzumab/taxane
bl1-subtype
prospectiveNestedCase-controlStudy
186S
vdrExpression
hormonalContraceptionUse
fewLmics
itsFirstDescription
currentBio-sensingTechniques
contrastAgents
freshLeafEthanolicExtract
nano-genosensor
S10
solidTumor
relapse
capacities
greatestDivergences
recurrence-free-survival
12-15Percecnt
ironOxideNanoparticles
tumorAccumulation
balfContent
regressionModel
historyPhysicalExamFindings
higherRisk
extendedAdjuvantTreatment
AMD3100
geometries
99Percecnt
Comparisons
Hyperprolactinemia
newerDrugDeliveryStrategies
similarSeriousAdverseEvents
microRNA-22
coxModels
patient'sTumorBurden
importantRole
theirSelection
DOACs
26
perceivedWorkAbility
salpingo-oophorectomy
undifferentiatedNeoplasticCells
magneticResonanceImaging
geneticChanges
woman
SUM159PT
breastUltrasound
systems
Utilization
pdgfs/pdgfrsAxis
specificSubtype
interaction
analyses
highestSe
deepLearning
breastImagingModality
hotIssue
undergoing
pathway
aberrances
lowCtnLevels
gaslessRobot-assistedNipple-sparingMastectomy
encapsulatedSuperparamagneticIronOxideNanoparticles
cellCultureSupernatants
NLR
significantAdvances
SMARCAD1
Women
expression
aptamerMf3
spc24Knockdown
switch
essentialsRisk
compactSynchrotronSources
chemotherapyDrugs
Uncertainties
proportion
options
adhesionProtein-1
-1
everolimus-exemestaneCombination
twoIndependentReviewers
radiotherapy
commonCancerTypes
breastCancerProgression
disturbance
meta-analyses
their
commonOnes
aberrantMethylationDetection
parpInhibitors
bloodVesselsFormation
Biopsy
factors
mainMeasures
backgroundTrastuzumab
vdrPolymorphisms
seromaProduction
approach
Univariate
vitaminD
22Deaths
commonPrimaryLesion
surgery
highSensitivity
staining
chemotherapyRegimens
stagingSystems
large-scaleStudies
non-hodgkinLymphoma
ssdnaAptamerMf3
evidence
mortalityRate
evidence-basedRecommendations
convolutionalNeuralNetworks
sosValues
riskFactors
microRNA
hyperglycemia
targetVolume
firstTime
retrospectiveReview
multipleGeneticAberrances
aim
combinedAnalysis
postmenopausalWomen
mostPretermBirth
mass/es
most
clinicalRecords
usStandardization
leafMda-mb-231CellDeath
recentEpigenomeStudies
combination
familyMembers
workAbility
25-year-oldWoman
immediateReconstruction
westernBlotting
shorterRadiotherapyRegimens
her2-targetedTherapies
skinMetastasis
superiorVenaCavaSyndrome
directEffects
numerousGene-expression-basedPrognosticSignatures
increases
prognosticValue
immunohistochemicalProliferationMarkerKi67
traumaticBreastNeuromas
divergences
Mammographic
biologicalHeterogeneity
additionalInformation
secondTumor
absence
induction
medianLatencyPeriod
development
lymphoma
metastasis-free
medicalKnowledge
geneExpressionLevel
majority
fpReductionTechnique
elevenPatients
BRCAs
simulatedBreastCancer
secondaryLymphomatousInvolvement
maintenance
higherBalfContent
cutoff
definedSubtype
humanChorionicGonadotropin
solubleMarkers
significantHigherRisk
incidenceRates
breastScreening
Follow-up
textureAnalysis
networks
main
breastCancerScreening
CTCs
asymptomaticWomen
dose
alternative
covariance
stageIv
high-gradeSarcomas
baselineSt-2Level
100Patients
tolerabilitytheApatinib
sustainedStableDisease
muchInterest
variation
survivalRates
studies
breastCancer
VEGF-D
Validation
syndrome
People
outcomes
oralBeta-sdgAdministration
clinicopathologicalSignificance
Efforts
currentAnalysis
diagnoses
Diagnosis
lowerNewBloodVesselsFormation
ERN
osAdvantage
mixedMethodsDesign
sensitiveCells
characterization
omegaFattyAcids
third
Fisher
cause
inImaging
eighthEdition
complaint
littleHelp
idiopathicGranulomatousMastitis
control
STAT1
biomarkers
oncologyGroup
breastCancer-specific10-yearSurvival
manyWomen
27-36MillionPatients
charts
mitochondrialTransmembranePotential-drivenRegulatedCellDeaths
PAX8
mitochondrialMorphology
people
surgeon
geneExpressionData
chemotherapy-inducedNeuropathy
wordCloud
increasedPer2Expression
lowerCumulativeHazardRates
growthPotential
83Percecnt
SP
nsaidsExposure
roboticSystem
correlationCoefficient
multidimensionalScaling
Drp1
breastCancerRelapse
regressionAnalyses
Baicalin
efforts
133Controls
unbiasedRnaSequenceAnalysis
diagnosticEvaluation
bioactivity
markedReduction
p27
increasedRisk
presence
ourProposedMethod
two-yearStudy
glut1Expression
30Cm
provision
barcodeMode
risk
100000Person-years
metabolicChanges
prostateCancers
breastBiopsies
interval
lowClassificationAccuracies
itsDeregulation
inverseLongitudinalAssociation
kmt2aFusionGenes
mainContribution
higher
earlyBreastCancerDetectionSystems
breastNeuromas
therapy
mriProtocols
theirCardiotoxicities
dichlorofluoresceinLevel
haveCenterstage
1000Patients
PFS
identified
furtherStudies
inhibitors
blackWomen
colonyFormation
bilateralInvolvement
rareTumor
aspects
serumCrust
reverseTranscription-quantitativePolymeraseChainReaction
coxHazardRegressionModels
Development
subjectiveRisk
medianLatencyTime
+239Percecnt
4248BreastCancerPatients
involved
majorAdvance
DDTs
conventionalX-rayMammography
optimalCutoffValues
23Patients
brcc3Interference
mostPatients
adults
circRNAs
14644Patients
effect
Lack
lowHealthLiteracy
youngestCohort
figures
age
tissueBiopsy
428BreastCancerPatients
their5h-pyridoPyrrolizin-5-oneAnalogs
medianAge
transcoelomic
TAAs
informationNeeds
lymphNodeRatio
changes
tumorInformation
mpMRI
optimalCut-offValue
160Patients
study'sObjectives
Probes
kmt2aFusionGeneTranscripts
imageSegmentation
measurements
aspirinTherapy
newFpReductionTechnique
immunocytochemicalStudies
relatedTranscriptionFactorSox9
herPresentation
beta-SDG
otherAgeGroups
directRelationship
delay
obtainedFeatures
receptorTyrosineKinasePdgfrb
stableDrug-carrierBinding
occultBreastTumors
secondValuedApproach
cardiacTroponins
promoterdnaMethylation
chemotherapy
mammographicImages
similarities
patient'sHistory
lesions
Use
state-of-the-artAlgorithms
morcFamilyCw-typeZincFinger4Overexpression
700
amino-terminalFragment
outliers
practitionersKnowledgeable
experts
study
lateComplications
tissueBiopsy
Lesions
target
12331Non-nsaidUsers
chemotherapyHormonalTreatment
craniotomy
five-yearMetastasis-free
incorporation
expressionLevels
erysipelatoidCarcinoma
responseRate
nippleInvolvement
considerations
lessBleeding
all
oncoproteins/cancerSuppressors
TAG72
cleftLip/palate
aromataseInhibitor-inducedBoneLoss
medianInterval
hospitalizations
metastaticDisease
microfluidicPlatform
twoPathways
regressionAnalysis
vap-1Expression
priorMedicalHistory
systematicCharacterization
metabricTrainingSet
variousMethods
simpleLow-costAlternative
lymphocytes
drugDeliveryStrategies
Cases
tumor
mortality
tumourigenesis
Zt/g4-MMAE
phosphotyrosineProteinComplexes
screeningStrategy
preventiveStrategies
obesity
multiplexAssay
bleedingRisk
epigeneticAberrations
splenicLymphocytes
adjuvantRadiotherapy
cancerTherapy
furtherStudies
lisbonRegion
breastCancerPatients
differentiation
polymeraseChainReaction
manyComputerVisionApplications
carboxyl-modifiedPegylatedPoly
DCR
Tumours
dnaMethylation
womenCarriers
dissection
examination
overview
denosumabInjection
20BreastCancerPatients
8155Patients
signalIntensity
mostBreastDiseases
rareCases
plasmaLevels
cancerFibroblasts
eralphaTranscription
factorAnalysis
CellLines
skinMetastases
Studies
publicHealthCareSystem
rituximab
SD-CNN
rs5743810
subtypes
vitaminDActivity
ESR1
radiomics
brcanessPhenotype
tools
acuteComplications
medianTime
method
measurementSystem
numberVariants
Tamoxifen
proteinKinaseC/extracellularSignal-regulatedKinasePathway
f-fdgPet/ct
prognosticStagingSystems
conservativeTreatment
markers
goal
furtherDevelopment
additionalAnalyses
water
featureSelectionMethod
overallSurvival
aberrantExpression
Hsa_circ_000178
numerousStudies
cowdenSyndrome
successfulQuantification
mostTumors
difference
herDisease
association
alternativeContrast-enhancedScreeningTools
miR-34s
mrnaLevels
almatyCity
lifestyleFactors
theirInhibition
QALY
dual-luciferaseReporterAssays
positronEmissionTomography
occurringCancers
localizedDescription
linkage
problem
incidenceRates
mriTechniques
entities
49Patients
coxModel
blockade
advancedBreastCancerBearingMutations
three-yearSurvivalRates
fineNeedleAspirationCytology
breastCancer
wavelengthConsistencyIndex
Residents
9398
matchedHealthyTissues
miR-10a
axillaryDissection
neoadjuvantTreatment
ourProposedMethod
informationNeedsVary
receptorActivator
cancerAssociatedFibroblasts
anti-her2Therapies
miRNA
bivariateAssociations
c.
strategy
cutoffValues
continuousPattern
circularRnas
It
decreasedRisk
Progranulin
document
polycysticOvarySyndrome
appropriateSequencing
gsAlgorithm
fluorescenceImagingExVivo
CNN
mrSystems
gastricCancer
betterPredictionPerformance
directTargetGene
totalOf121Patients
traumaticNeuroma
breastCancerTreatment
952PercecntOfthePostmenopausalWomen
jak-statPathway
members
Belgium
caloricRestriction
enhancerRegions
advances
pathologicalSpecimen
c1711
virtualReality
breastCarcinomas
novelty
muchFocus
needleAspirationCytology
lungAdenocarcinomas
cutaneousMetastasis
Cabergoline
positiveTreatment
pathologicalResults
breastCancerMetastasis
treatmentProtocols
twoTumorGroups
those
block
familySupport
SPIO
support
twoScales
Estrogen
proposedCovariance
cells
networkOutput
repair
selectiveBinding
trend
PM
Circ-EFCAB2
RON
importantNumber
acceleratedPartialBreastIrradiation
aggressiveManagement
caDetection
breastCancerScreening
targetingFxyd3-mediatedPathway
radiomicsScore
underlying
Scoring
vascularAdhesionProtein-1
Prevalence
estrogenReceptor
stigmatization
largeVariability
flankingCgi
platform
cancerSusceptibilityGenes
greatestImportance
comprehensiveResearchData
programs
exosomesCk19
Genetic
segmentationAlgorithm
Literature
occasionalComplications
dynamicSh2ProteinComplexes
counseling
novelMethod
pharmacologicalInduction
measures
it
interview
ageGroups
trajectoryMembership
peripheralBloodSamples
dynamicContrast
freshLeafEthanolicExtract-treatedMda-mb-231CellDeath
mtorInhibitorEverolimus
exposure
definition
period
papers
breastCancer
mastectomizedWomen
result
molecularRegulatoryNetworks
latencyTime
towaveletFilter
mammograms
Number
primaryTumours
133BreastCancerCases
latencyPeriod
coxHazardRegressionAnalysis
monteCarloFeatureSelection-basedFeatureSelection-basedComputationalMethod
2921Posts
Co-existence
frequentLateRelapses
obstetrician
ourBreastCancerPatients
chemotherapy-inducedNeuropathy
steps
irregularHyperintenseLesion
finding
these
drugTherapy
research
of121Patients
involvement
Biomarkers
techniques
triple-negativeBreastCancer
carcinoma
late-stage
balfLevel
Steps
population
alexnetModels
randomisedTrials
accuracy
paradigmaticExamples
multivariateCoxProportionalHazardRegressionAnalysis
decreases
ca15-3Detection
predictors
exosomes
oneHundredElevenPatients
nsaidUsers
rs5743810ProAllele
cancerSurvivors
mir-10aExpression
triple-negativeBreastCancer
intraoperativeScrapeCytology
regressionModels
pik3caMutations
ratio
follow-up
signatures
transferLearning
fibroblastsAdjacent
mStage
concerns
sosReconstruction
medianOverallSurvival
China
subtype-specificSignature
baselineSolubleSt-2Level
routineUse
hugeImprovement
treatments
12404Patients
-916
DESI-MSI
compounds19a
speed
pfBiomarkers
smallProportion
microscopicTesting
resultsAberrantExpression
hsa-miRNA-143-3p
PALB2
twoChlorambucilPlatinum
australianSynchrotron
combinedPanel
low-molecular-weightHeparin
internationalGuidelines
5Percecnt
microrna-22ExpressionLevels
suchSymptoms
paraneoplasticNeurologicSyndromes
higher-qualityImaging
hazardRates
probableAnticancerMechanisms
transport
shallowCnn
bloodSamples
recurrenceRates
highestRisk
SOX9
image
substantialRacial/ethnicDisparity
anticoagulantChoice
neuropathy
molecularChanges
potentialReduction
itsUsefulness
27b
kaposiSarcoma
furtherResearch
breast
oxidativeStressProbe
MethyLight
limitedHealthSystemCapacities
ourMethod
properties
helaCells
Rituximab
theranosticNanoplatform
breastCancerGenetics
therapies
experiences
metastaticDisease
medianOverallSurvival
trials
statisticalClassifiers
limitedLiterature
correctDiagnosis
breastCancerDetectionMethod
clb-pt-clbProdrug
Ki67
higherProportion
microfluidicChips
screeningTools
survivalDistributions
perfluorohexane
featureSubsets
each
occurrence
simulation
paclitaxel
clinicalCharacteristics
estrogen
tailoredConsiderations
BRCC3
bleedingRates
oneMutation
time
toxicity
ORR
terms
mechanism
FOXC1
ourStudy
criticalScientificBase
selectedPatients
usefulness
overallMedianSurvival
diseases
literature
algorithm
longNoncodingRnas
complexSemisolidMasses
racialDisparity
currentUtilizedHistopathologicBiomarkers
per2Expression
pyrrolizin-9-one
pax6Overexpression
Diseases
Non-linearity
lack
controlTrial
value
ddtExposure
remarkableEnzyme-activatedNirFluorescentProbeNir-sn-ggt
humanPapillomavirusScreening
ourLiteratureReview
PB-DLL
intensive
autoimmuneDiseases
separateClassificationModels
quality
theirLong-termSurvival
clinicians
invasion
model
multivariate
costData
Cells
pD1542yMissenseMutation
Sutegorization
number
Recurrences
lungCancers
tumorSite-specificInformation
superiorVenaCavaSyndrome
proposedMethod
diagnosis
clinicalPicture
massProduction
Researchers
hundreds
appropriateInterpretation
hsa_circRNA_102101
mab1e3
confidentDiagnoses
detection
screeningPrograms
inverseProblem
omission
brcc3Expression
circularRnas
targetedTherapies
epigeneticDysregulation
skinMetastasis
treatmentOutcomePrediction
nanoplatform
overallSurvival
protocols
recurrentWords
sensitivity
supportVectorMachine
AION
detectionofBreastCancer
mostCommonOnes
biocompatiblePfh-ptx@plga
contrast-enhancedSpectralMammography
complexSurgeries
Cryopreservation
top10InformationalNeedContents
cTn
sixCirculatingMirnas
oxidationPeakCurrent
moreIntensiveFollow-up
foxc1Function
neuroma
breastReconstruction
comparisons10-yearSurvival
CEDM
erEvaluation
intervention
anti-her2Therapy
tamoxifen
relativeHospitalizedBleedingRisk
evolutionaryConservedCircularRnas
focalAsymmetricDensity
tumorGroups
proteinExpression
CLP
reports
proposedAlgorithm
neuropathies
Promoting
35-64Years
increasedRonExpression
OR
the
cohort
cancerStaging
underlyingCauses
fission
CGI
VAP-1
breastCancerPatients
familialCancerClustering
invasiveDuctalCarcinoma
localRecurrence
remarkableImprovements
65-year-oldFemale
necessity
56Patients
nondestructiveTesting
coverageRates
surfaceMorphology
riskFactors
tumorInterstitialFluidDerivedExosomes
detailedRoles
strongContrast
tumorFluid
objective
inhibition
assay
chemotherapyGroups
respondents
pooledUptake
patient
standardizedImagingProtocol
metabolicTargetVolume
strategies
complications
fpReduction
variousNon-pharmacologicalAdjuvantTherapies
overallMediumSecondTumor-freeTime
volumes
msotImaging
fibroblasts
challenge
Applications
cut-offBalfLevel
significance
pax6promoterMethylation
Management
sexualityEvidence
features
significantIncrease
Inhibition
extremeLearningMachineClassification
drugBinding
adjuvantEndocrineHormonalTherapy
histopathologicalreports
cases
characteristicExosomalTumorMarkers
multiparametricMri
use
threeParadigmaticExamples
Speed-of-sound
advancedBreastCancer
increasedRisk
1444Women
brd4PharmacologicalInhibition
scan
Breast
medicalStatus
PFH-PTX@PLGA
menopause
available
metformin
abnormalDnaMethylation
commonCancer
malePatients
Pyrrolizinones
tendinopathy
recentDevelopments
cancerResearch
targetedTherapies
pleuralMetastasis
infertility
keyRole
ivimParameters
ptyrProteins
nuclearAtypiaScoring
12SampledWomen
firstDose
breastSurvival
differentialExpression
ipsilateralBreastRecurrence
Importantly
comparison
fewStudies
mPatients
imagingFeatures
recognizingMethylationStatus
estrogenReceptorBeta
morc4Silencing
10-foldCross-validation
roles
tumours
Acupuncture
standard
tumorWeight
chlorambucilPlatinum
reporterAssays
erythema
prospectiveStudies
tumorSuppressorFunction
leafExtract
axillarySurgery
prediction
newCancerCases
hospitalCohort
furtherAdvancements
keyHypomethylationSites
ourAim
vap-1NegativeStaining
healthcareUtilization
output
Risk
ctcIsolationTechniques
Computer
adherence
parameterUncertainty
rates
adPatients
volumetricMeasurementSystem
substantialImprovements
histopathologicDistinction
sevenWomen
ourMethod
guidelines
Differentiation
nippleAreolaComplexInvolvement
improvedDetection
89Participants
underlyingIncrease
differentPrognosis
robustSynthesisMethods
youngMalePatients
rnaKnockdown
bindingSites
481Women
pulmonaryMetastases
relapseRates
modificationPathways
Therapies
clinicalDepression
circulatingSolubleRankl
synchrotronSources
ourPatient
Articles
growth
capillaries
highGlut1Expression
higherDetectionRates
hospitalizedBleedingRisk
otherInotherTertiaryCentres
mirnaExpressionProfiles
threePapers
online
paTreatment
probableMechanisms
first-lineTreatment
accurateMethod
availableContrastAgents
tangshanPeople
ERBB2
autoantibodies
longitudinalAssociation
principles
mostNondestructiveTests
resistance
Targeting
histoneModifications
binding
similarExperimentalParameters
manyPatients
Epidemiology
monteCarloFeatureFeatureMethod
pseuderanthemumPalatiferumRadlkExtracts
18FemaleNudeMice
postOperativeAssessment
progranulin
inflammatoryTumour
Period2
baicalin
three-lncrnaSignature
fisherAnalysis
rapidAdvancements
severalHer2-targetedTherapies
Transcripts
higherResolution
activity
upregulation
incidenceTrendPlots
disruption
nirProbeNir-sn-ggt
one-thirdCases
brd4Inhibition
hybridCultures
response
clinicalBreastExamination
10Percecnt
pathways